Advancing hope for those facing mantle cell lymphoma.
We connect patients, caregivers, and researchers with trusted information, expert-guided support, and the research needed to improve outcomes.
The Mantle Cell Lymphoma Alliance supports those facing mantle cell lymphoma with trusted information and expert-guided support. We connect patients, caregivers, researchers, and oncologists across all clinical settings to improve outcomes and expand access to care. We support targeted research that advances progress toward better treatments and ultimately a cure.
What We Do
Three pillars guiding our mission to transform outcomes for those affected by MCL.
Advancing Research
We fund and support targeted research that moves us closer to better treatments and ultimately a cure for mantle cell lymphoma.
Trusted Education & Access
We provide clear, medically reviewed information and connect patients with the specialists and resources they need.
Collaboration & Community
We bring together patients, caregivers, researchers, and clinicians to share knowledge and build a stronger MCL community.
MCL by the Numbers
Understanding the scope of mantle cell lymphoma.
Statistics sourced from published medical literature including the American Cancer Society and the Leukemia & Lymphoma Society.
Stories, updates, and expert guidance from the MCL community.
Keep up with the newest MCLA articles, research updates, and community news.
Larry's Story: Living with MCL Since 2012
Larry Fagan, an MCLA Board Member, was diagnosed with mantle cell lymphoma in 2012 — just after retiring and his son's college graduation. He shares his treatment journey at Stanford, the unusual way he learned about his diagnosis, and how an online community of MCL patients eventually led him to help start the MCLA.
Sonrotoclax
Next-Generation Therapy Sonrotoclax Receives FDA Approval
Newly approved therapy expands treatment choices and signals continued progress for people living with MCL. Sonrotoclax (brand name Beqalzi) is the first BCL-2 inhibitor formally approved for mantle cell lymphoma, cleared for patients whose disease has returned or stopped responding after at least two prior treatments.
Mosunetuzumab + Polatuzumab vedotin
Targeted Immunotherapy Combo Shows Strong Results in Relapsed Mantle Cell Lymphoma
A new Phase 2 study published in Blood in April 2026 reports an 88% response rate for a fixed-duration combination of mosunetuzumab and polatuzumab vedotin in patients with mantle cell lymphoma whose disease has returned after a BTK inhibitor.
Stay Informed. Join Our Community.
Receive the latest updates on MCL research, patient resources, and community events delivered to your inbox.